title: Altered pharmacokinetics of cimetidine caused by down-regulation of renal rat organic cation transporter 2 (rOCT2) after liver ischemia-reperfusion injury.
abstract: The renal tubular secretion of cationic drugs is dominated by basolateral organic cation transporter 2 (rOCT2/SLC22A2) and luminal multidrug and toxin extrusion 1 (rMATE1/SLC47A1). Little is known about the variation in the expression of these renal transporters after liver ischemia-reperfusion (I/R) injury. Here, we examined the pharmacokinetics of a cationic drug, cimetidine, and renal rOCT2 and rMATE1 levels as well as their regulation after liver I/R. Rats were subjected to 60 min of liver ischemia followed by 12 h of reperfusion. The antioxidant Trolox was administered intravenously 5 min before reperfusion. The systemic and tubular secretory clearances of cimetidine (78% and 55%) as well as renal rOCT2 and rMATE1 levels (67% and 61%) in I/R rats were decreased compared with those in sham-operated rats, respectively. However, the renal tissue-to-plasma concentration ratio but not the renal tissue-to-urine clearance ratio of cimetidine was decreased after liver I/R. Moreover, Trolox prevented the decreases in renal rOCT2 levels and systemic clearance of cimetidine after liver I/R. These results demonstrate that liver I/R decreases the tubular secretion of cimetidine, mainly because of the decreased rOCT2 level in the kidney, and that oxidative stress should be responsible in part for decreased renal rOCT2 after liver I/R injury.
authors.affiliation: College of Pharmacy, Kinjo Gakuin University.
authors.forename: Kenji
authors.initials: K
authors.lastname: Ikemura
authors.forename: Erika
authors.initials: E
authors.lastname: Nakagawa
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Kurata
authors.forename: Takuya
authors.initials: T
authors.lastname: Iwamoto
authors.forename: Masahiro
authors.initials: M
authors.lastname: Okuda
mesh_terms: D000818:Animals; D017920:Antiporters / Q000096:biosynthesis / Q000378:metabolism*; D002839:Chromans / Q000494:pharmacology; D002927:Cimetidine / Q000493:pharmacokinetics* / Q000652:urine; D015536:Down-Regulation; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008297:Male; D029362:Organic Anion Transporters, Sodium-Independent / Q000096:biosynthesis; D027701:Organic Cation Transport Proteins / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000378:metabolism*; D000075102:Organic Cation Transporter 2; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000503:physiopathology*
chemical_list: D017920:Antiporters; D002839:Chromans; D029362:Organic Anion Transporters, Sodium-Independent; D027701:Organic Cation Transport Proteins; D000075102:Organic Cation Transporter 2; C100590:Slc22a2 protein, rat; C515734:Slc47a1 protein, rat; C114338:organic anion transport protein 3; D002927:Cimetidine; C010643:6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid